*July 2021*
Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) in the first line setting are the key to unlocking the next wave of success in treating lung cancer, according to Jonathan W. Riess, MD, MS, associate professor of medicine at the University of California School of Medicine, UC Davis Comprehensive Cancer Center.1
The largest hurdle facing investigators is identifying and overcoming resistance mechanisms. First-and-fourth-generation (TKIs) in combination with osimertinib may prevent the emergence of known resistance mechanisms, particularly C797S; however, the future of care will lean heavily on the identification of more actionable targets.
Riess provided an overview of the available data for osimertinib, establishing its role in the present and future of care for patients with EGFR-mutant non–small cell lung cancer (NSCLC) as part of the 22nd Annual International Lung Cancer Congress.
